A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects
AbstractPurpose QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S biosimilar in healthy Chinese male subjects.Design A randomised, double-blind, two-arm, parallel study was performed to examine th...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2021.1887925 |
| _version_ | 1797385729079246848 |
|---|---|
| author | Hong Zhang Xiaojiao Li Jingrui Liu Cuiyun Li Min Wu Xiaoxue Zhu Jixuan Sun Min Fang Yanhua Ding |
| author_facet | Hong Zhang Xiaojiao Li Jingrui Liu Cuiyun Li Min Wu Xiaoxue Zhu Jixuan Sun Min Fang Yanhua Ding |
| author_sort | Hong Zhang |
| collection | DOAJ |
| description | AbstractPurpose QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S biosimilar in healthy Chinese male subjects.Design A randomised, double-blind, two-arm, parallel study was performed to examine the bioequivalence of QX003S (8 mg/kg) with that of Actemra® as a reference drug.Results QX003S (N = 40) and Actemra® (N = 40) groups exhibited similar PK properties. The inter-subject variability ranged from 14.95% to 18.78%. The 90% confidence intervals of the ratios for Cmax, AUC0–t andAUC0–∞ in both groups were within the range of 80–125%. After administration, the number of subjects who tested positive for anti-drug antibodies (ADA) in the QX003S group and Actemra® groups was 6 (14.3%) and 14 (34.1%), respectively. Adverse reactions occurred in 100% and 97.6% subjects in the QX003S and Actemra® groups, respectively. The most common adverse reactions were decrease in fibrinogen level and neutrophil and leukocyte counts.Conclusion The PK characteristics and immunogenicity exhibited by QX003S were similar to that of the reference product, Actemra®. The safety profile was similar in the two treatment groups with mild-moderate adverse effects.Trial RegistrationThe trial is registered at Chinese Clinical Trial website (http://www.chinadrugtrials.org.cn/index.html#CTR20190002)Key pointsThis was the first clinical report of a new proposed tocilizumab biosimilar, QX003S.This phase-I randomized, controlled study compared pharmacokinetics, variability,immunogenicity, and safety of QX003S vs. the approved tocilizumab product (Actemra@).The results demonstrate bioequivalence between BAT1806 and the reference products (Actemra@), as well as comparable immunogenicity, safety and tolerability profiles. |
| first_indexed | 2024-03-08T21:58:27Z |
| format | Article |
| id | doaj.art-d226eed6d169454286b7c306314fa8f9 |
| institution | Directory Open Access Journal |
| issn | 0785-3890 1365-2060 |
| language | English |
| last_indexed | 2024-03-08T21:58:27Z |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj.art-d226eed6d169454286b7c306314fa8f92023-12-19T16:46:27ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602021-01-0153137538310.1080/07853890.2021.1887925A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjectsHong Zhang0Xiaojiao Li1Jingrui Liu2Cuiyun Li3Min Wu4Xiaoxue Zhu5Jixuan Sun6Min Fang7Yanhua Ding8Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaPhase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaPhase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaPhase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaPhase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaPhase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaPhase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaQyuns Therapeutic Co. Ltd., Taizhou City, Jiangsu Province, ChinaPhase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaAbstractPurpose QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S biosimilar in healthy Chinese male subjects.Design A randomised, double-blind, two-arm, parallel study was performed to examine the bioequivalence of QX003S (8 mg/kg) with that of Actemra® as a reference drug.Results QX003S (N = 40) and Actemra® (N = 40) groups exhibited similar PK properties. The inter-subject variability ranged from 14.95% to 18.78%. The 90% confidence intervals of the ratios for Cmax, AUC0–t andAUC0–∞ in both groups were within the range of 80–125%. After administration, the number of subjects who tested positive for anti-drug antibodies (ADA) in the QX003S group and Actemra® groups was 6 (14.3%) and 14 (34.1%), respectively. Adverse reactions occurred in 100% and 97.6% subjects in the QX003S and Actemra® groups, respectively. The most common adverse reactions were decrease in fibrinogen level and neutrophil and leukocyte counts.Conclusion The PK characteristics and immunogenicity exhibited by QX003S were similar to that of the reference product, Actemra®. The safety profile was similar in the two treatment groups with mild-moderate adverse effects.Trial RegistrationThe trial is registered at Chinese Clinical Trial website (http://www.chinadrugtrials.org.cn/index.html#CTR20190002)Key pointsThis was the first clinical report of a new proposed tocilizumab biosimilar, QX003S.This phase-I randomized, controlled study compared pharmacokinetics, variability,immunogenicity, and safety of QX003S vs. the approved tocilizumab product (Actemra@).The results demonstrate bioequivalence between BAT1806 and the reference products (Actemra@), as well as comparable immunogenicity, safety and tolerability profiles.https://www.tandfonline.com/doi/10.1080/07853890.2021.1887925Tocilizumabbiosimilarimmunogenicitypharmacokineticsinter-subject variability |
| spellingShingle | Hong Zhang Xiaojiao Li Jingrui Liu Cuiyun Li Min Wu Xiaoxue Zhu Jixuan Sun Min Fang Yanhua Ding A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects Annals of Medicine Tocilizumab biosimilar immunogenicity pharmacokinetics inter-subject variability |
| title | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects |
| title_full | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects |
| title_fullStr | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects |
| title_full_unstemmed | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects |
| title_short | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects |
| title_sort | randomized phase i pharmacokinetic trial comparing the potential biosimilar tocilizumab qx003s with the reference product actemra r in chinese healthy subjects |
| topic | Tocilizumab biosimilar immunogenicity pharmacokinetics inter-subject variability |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2021.1887925 |
| work_keys_str_mv | AT hongzhang arandomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT xiaojiaoli arandomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT jingruiliu arandomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT cuiyunli arandomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT minwu arandomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT xiaoxuezhu arandomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT jixuansun arandomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT minfang arandomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT yanhuading arandomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT hongzhang randomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT xiaojiaoli randomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT jingruiliu randomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT cuiyunli randomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT minwu randomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT xiaoxuezhu randomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT jixuansun randomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT minfang randomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects AT yanhuading randomizedphaseipharmacokinetictrialcomparingthepotentialbiosimilartocilizumabqx003swiththereferenceproductactemrainchinesehealthysubjects |